Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Memorial Sloan Kettering Cancer Center
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed non-small cell lung cancer with metastatic disease detected on cross-sectional imaging with a plan for one of the following systemic therapies:
* Carboplatin/paclitaxel
* Carboplatin/paclitaxel/pembrolizumab
* Carboplatin/pemetrexed
* Carboplatin/pemetrexed/pembrolizumab
* Pembrolizumab (single agent or in combination with other regimens in this list)
* Cisplatin/pemetrexed
* Cisplatin/pemetrexed/pembrolizumab
* Pemetrexed/pembrolizumab
* Pemetrexed
* Nivolumab (single agent or in combination with other regimens in this list)
* Ipilimumab/nivolumab
* Carboplatin/etoposide
* Carboplatin/etoposide/atezolizumab
* Cisplatin/etoposide
* Cisplatin/etoposide/atezolizumab
* Durvalumab (single agent or in combination with other regimens in this list)
* Atezolizumab (single agent or in combination with other regimens in this list)
Patients eligible for the systemic therapy regimens notes
Patients with Stage IV NSCLC who have symptomatic (defined by patient-reported cough, dyspnea, or hemoptysis) or near-symptomatic (determined radiographically to be threatening the airway, esophagus or vasculature) centrally located.
KPS ≥ 60
Age ≥ 18 years.
Able to provide informed consent.
Patients at reproductive potential must agree to practice an effective contraceptive method.
You may not be if
Previous radiotherapy to the intended treatment site that precludes developing a treatment plan that respects normal tissue tolerances.
Serious medical co-morbidities precluding radiotherapy.
Pregnant or breast-feeding women.
Clareo Health | Radiation Therapy to Relieve Symptoms in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
